Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 203

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 203
---
 $112.20 (as adjusted for stock splits, stock dividends,
stock combinations, recapitalizations and similar events). The December 2024 Common Warrants are exercisable beginning six months after
the issuance date (the “Initial Exercisability Date”) and expire on the third anniversary of the Initial Exercisability Date.
The December 2024 Common Warrants require “buy-in” payments to be made by us for failure to deliver any shares of Common Stock
issuable upon exercise. If at the time of exercise of the December 2024 Common Warrants, there is no effective registration statement
registering the shares of the Common Stock underlying the December 2024 Common Warrants, such warrants may be exercised on a cashless
basis pursuant to their terms.

On January 6, 2025, the Company
issued warrants to purchase an aggregate of 8,193 shares of Common Stock to certain investors affiliated with each other to induce investors
to exercise their Series A Preferred Warrants for cash (the “January 2025 Common Warrants”). The January 2025 Common Warrants
are exercisable for cash at an initial exercise price equal to $116.40 (as adjusted for stock splits, stock dividends, stock combinations,
recapitalizations and similar events). The January 2025 Common Warrants are exercisable beginning six months after the issuance date (the
“Initial Exercisability Date”) and expire on the third anniversary of the Initial Exercisability Date. The January 2025 Common
Warrants require “buy-in” payments to be made by us for failure to deliver any shares of Common Stock issuable upon exercise.
If at the time of exercise of the January 2025 Common Warrants, there is no effective registration statement registering the shares of
the Common Stock underlying the January 2025 Common Warrants, such warrants may be exercised on a cashless basis pursuant to their terms.

If we issue options, convertible
securities, warrants, shares, or similar securities to holders of Common Stock, each holder of December 2024 Common Warrants and January
2025 Common Warrants have the right to acquire the same as if the holder had exercised its December 2024 Common Warrants or January 2025
Common Warrants. The holders of December 2024 Common Warrants and January 2025 Common Warrants are entitled to receive any dividends paid
or distributions made to our holders of Common Stock on an “as if converted” basis